Administration of bleomycin resulted in a significant increase in the lung index (777% ± 0.72%). The SalB (0.45 mg/kg) group exhibited a marked reduction in the lung index (4.21% ± 0.24%) after 28 days of treatment. It also reduced the levels of hydroxyproline (HYP), collagen type I (Col-1), tissue factor (TF), and related coagulation factors induced by BLM, while simultaneously decreasing the expression of plasminogen activator inhibitor-1 (PAI-1), thereby delaying the progression of pulmonary fibrosis in rats (Zhang et al., 2021). The gene discussed is PHEX; the disease is pulmonary fibrosis.